Total Payments
$248,518
2023 Payments
$198,746
Companies
3
Transactions
40
Medicare Patients
2,508
Medicare Billing
$145,424
Payment Breakdown by Category
Research$248,478 (100.0%)
Gifts$20.00 (0.0%)
Education$19.81 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $248,478 | 38 | 100.0% |
| Gift | $20.00 | 1 | 0.0% |
| Education | $19.81 | 1 | 0.0% |
Payments by Type
Research
$248,478
38 transactions
General
$39.81
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $198,263 | 24 | $0 (2023) |
| Eli Lilly and Company | $50,235 | 15 | $0 (2023) |
| Merck Sharp & Dohme LLC | $19.81 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $198,746 | 26 | PFIZER INC. ($198,243) |
| 2022 | $1,266 | 5 | Eli Lilly and Company ($1,266) |
| 2021 | $39,510 | 5 | Eli Lilly and Company ($39,490) |
| 2020 | $8,112 | 3 | Eli Lilly and Company ($8,112) |
| 2017 | $883.82 | 1 | Eli Lilly and Company ($883.82) |
All Payment Transactions
40 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/14/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $4,489.20 | Research |
| Study: A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS • Category: PAIN | ||||||
| 12/07/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $8,481.92 | Research |
| Study: PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 12/07/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $1,937.25 | Research |
| Study: PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 11/22/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $9,318.81 | Research |
| Study: PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 11/22/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $6,898.13 | Research |
| Study: PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 11/22/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $364.50 | Research |
| Study: PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 11/16/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $10,511.75 | Research |
| Study: PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 11/16/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $7,200.90 | Research |
| Study: A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS • Category: PAIN | ||||||
| 11/09/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $2,515.66 | Research |
| Study: PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 10/12/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $9,094.80 | Research |
| Study: A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS • Category: PAIN | ||||||
| 10/12/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $4,491.05 | Research |
| Study: PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 10/05/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $14,554.26 | Research |
| Study: PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 09/26/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $1,470.15 | Research |
| Study: PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 09/21/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $12,448.04 | Research |
| Study: PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 09/21/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $11,864.10 | Research |
| Study: A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS • Category: PAIN | ||||||
| 08/17/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $18,583.42 | Research |
| Study: PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 08/03/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $8,819.10 | Research |
| Study: A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS • Category: PAIN | ||||||
| 08/03/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $5,479.65 | Research |
| Study: PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 07/18/2023 | Merck Sharp & Dohme LLC | — | Education | In-kind items and services | $19.81 | General |
| Category: ENDOCRINOLOGY | ||||||
| 05/18/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $2,510.77 | Research |
| Study: PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 05/04/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $10,342.80 | Research |
| Study: A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS • Category: PAIN | ||||||
| 04/26/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $30,654.00 | Research |
| Study: A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS • Category: PAIN | ||||||
| 04/13/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $7,731.05 | Research |
| Study: PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 04/06/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $8,481.92 | Research |
| Study: PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 01/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $285.00 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS | PFIZER INC. | $82,465 | 7 |
| PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | PFIZER INC. | $82,086 | 9 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITH TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-2) | Eli Lilly and Company | $39,640 | 3 |
| PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | PFIZER INC. | $33,692 | 7 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | Eli Lilly and Company | $8,295 | 4 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC MIGRAINE - THE EVOLVE-1 STUDY | Eli Lilly and Company | $883.82 | 1 |
| PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 | Eli Lilly and Company | $446.53 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN PATIENTS 6 TO 17 YEARS OF AGE WITH EPISODIC MIGRAINE - THE REBUILD STUDY | Eli Lilly and Company | $400.00 | 2 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | Eli Lilly and Company | $285.00 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITH TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-2) | Eli Lilly and Company | $198.36 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA | Eli Lilly and Company | $86.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 628 | 835 | $166,154 | $33,839 |
| 2022 | 9 | 621 | 846 | $135,767 | $31,967 |
| 2021 | 11 | 560 | 874 | $146,796 | $35,933 |
| 2020 | 10 | 699 | 1,071 | $163,327 | $43,685 |
Total Patients
2,508
Total Services
3,626
Medicare Billing
$145,424
Procedure Codes
38
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 245 | 429 | $89,560 | $20,407 | 22.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 168 | 182 | $50,305 | $9,801 | 19.5% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 19 | 25 | $3,275 | $976.81 | 29.8% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 111 | 114 | $18,244 | $969.54 | 5.3% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 30 | 30 | $1,905 | $941.07 | 49.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 13 | 13 | $1,886 | $566.70 | 30.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 17 | 17 | $966.00 | $164.64 | 17.0% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 25 | 25 | $12.50 | $12.25 | 98.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 265 | 468 | $88,920 | $21,910 | 24.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 105 | 116 | $29,580 | $5,570 | 18.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 32 | 35 | $4,717 | $1,494 | 31.7% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 45 | 47 | $1,486 | $1,433 | 96.4% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 59 | 60 | $3,600 | $648.79 | 18.0% |
| 0064A | Adm sarscov2 50mcg/0.25mlbst | Office | 2022 | 12 | 13 | $806.00 | $531.02 | 65.9% |
| 99497 | Advance care planning, first 30 minutes | Office | 2022 | 49 | 51 | $6,630 | $358.30 | 5.4% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 42 | 43 | $21.50 | $21.14 | 98.3% |
| 91306 | Sarscov2 vac 50mcg/0.25ml im | Office | 2022 | 12 | 13 | $6.50 | $0.13 | 2.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 255 | 496 | $91,690 | $19,417 | 21.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 112 | 121 | $30,285 | $6,894 | 22.8% |
| 99309 | Subsequent nursing facility visit, typically 25 minutes per day | Office | 2021 | 18 | 67 | $9,715 | $4,338 | 44.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 24 | 27 | $4,860 | $1,891 | 38.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 38 | 47 | $5,875 | $1,369 | 23.3% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2021 | 18 | 20 | $2,500 | $839.04 | 33.6% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 37 | 37 | $1,110 | $655.71 | 59.1% |
| 0011A | Adm sarscov2 100mcg/0.5ml1st | Office | 2021 | 11 | 11 | $682.00 | $457.93 | 67.1% |
About Dr. David Fried, MD
Dr. David Fried, MD is a Internal Medicine healthcare provider based in East Greenwich, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/30/2005. The National Provider Identifier (NPI) number assigned to this provider is 1275520678.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Fried, MD has received a total of $248,518 in payments from pharmaceutical and medical device companies, with $198,746 received in 2023. These payments were reported across 40 transactions from 3 companies. The most common payment nature is "" ($248,478).
As a Medicare-enrolled provider, Fried has provided services to 2,508 Medicare beneficiaries, totaling 3,626 services with total Medicare billing of $145,424. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location East Greenwich, RI
- Active Since 09/30/2005
- Last Updated 04/09/2024
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1275520678
Products in Payments
- NURTEC ODT (Drug) $198,243
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in East Greenwich
Dr. Todd Viccione, Md, MD
Internal Medicine — Payments: $25,434
Internal Medicine $25,434
Dr. Jonathan Martin, M.d, M.D
Internal Medicine — Payments: $13,170
Internal Medicine $13,170
Dr. Richard Leach, Do, DO
Internal Medicine — Payments: $6,095
Internal Medicine $6,095
Dr. Shahid Khan, Md, MD
Internal Medicine — Payments: $4,742
Internal Medicine $4,742
Leah Marano
Internal Medicine — Payments: $576.35
Internal Medicine $576.35
Silvia Pena, Md, MD
Internal Medicine — Payments: $535.25
Internal Medicine $535.25